Inhibikase Q3 net loss $11.9M ($0.13/sh); advancing IKT-001 Ph2b in PAH

Inhibikase Therapeutics, Inc.

2025-Q3 EPS reported -$0.40 vs consensus -$0.13 ▼ miss (-204.6%)

Net loss $11.9M for Q3 2025 vs $5.8M YoY; cash $77.3M at Sep 30, down from $97.5M at Dec 2024.
R&D expenses $7.6M (Q3) vs $4.2M; includes $7.4M IPR&D write-off from CorHepta acquisition.
Plans to initiate Phase 2b IMPROVE-PAH trial of IKT-001 in Q4 2025 (150 pts; 300/500 mg or placebo).
Appointed Timothy Pigot as Chief Commercial and Strategy Officer.
To present at Jefferies Global Healthcare Conference on Nov 17, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.